Evidence map›Paper›PMID 37372428›Full record

ArticleGenes2023

Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling.

Leticia Sandoval, Wazim Mohammed Ismail, Amelia Mazzone, Mihai Dumbrava, Jenna Fernandez, Amik Munankarmy, Terra Lasho, Moritz Binder, Vernadette Simon, Kwan Hyun Kim and 5 more

Abstract read
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Leticia SandovalDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-6916-2249
Wazim Mohammed IsmailDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-1782-7296
Amelia MazzoneDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-6236-6962
Mihai DumbravaDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9045-6615
Jenna FernandezDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-0190-8673
Amik MunankarmyDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-7572-1169
Terra LashoDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-0315-5230
Moritz BinderEpigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9014-9658
Vernadette SimonMedical Genome Facility, Genome Analysis Core, Mayo Clinic, Rochester, MN 55905, USA.
Kwan Hyun KimEpigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-4975-2839
Nicholas ChiaMicrobiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9652-691X
Jeong-Heon LeeDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-4007-9166
S John WerohaDepartment of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Mrinal PatnaikEpigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Alexandre Gaspar-MaiaDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-8528-5575

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393
6 · The paper itself

Abstract

The snATAC + snRNA platform allows epigenomic profiling of open chromatin and gene expression with single-cell resolution. The most critical assay step is to isolate high-quality nuclei to proceed with droplet-base single nuclei isolation and barcoding. With the increasing popularity of multiomic profiling in various fields, there is a need for optimized and reliable nuclei isolation methods, mainly for human tissue samples. Herein we compared different nuclei isolation methods for cell suspensions, such as peripheral blood mononuclear cells (PBMC,

Indexed as

EpigenomicsLeukocytes, MononuclearHumansMultiomicsReproducibility of ResultsRNA, Small NuclearRNA, Small Nuclearepigenomic profilingnuclei preparationsingle-cell sequencingsnATAC-seqsnRNA-seq

Identifiers

PMID37372428
PMCPMC10297939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.